You are here: Industry Insights > pulmonary arterial hypertension

News List

Liquidia Resubmits New Drug Application for LIQ861 Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension drugs
May 24, 2021
Liquidia Corporation announced today that on May 7, 2021, it resubmitted its New Drug Application for LIQ861 for the treatment of pulmonary arterial hypertension.
Acceleron receives PRIME designation from EMA for Sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
May 06, 2020
Acceleron Pharma said that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
April 14, 2020
Acceleron Pharma announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Altavant Sciences Initiates Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension americanpharmaceuticalreview
August 07, 2019
Altavant has dosed the first patient in the ELEVATE 1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with pulmonary arterial hypertension (PAH).
Inhaled dry powder formulation of treprostinil works well in PAH patients europeanpharmaceuticalreview
January 16, 2019
A formulation of treprostinil as an inhaled dry powder has proven to be safe and effective, as reported in the safety analysis of a Phase III trial…
NHS England to fund Actelion's Uptravi pharmatimes
January 03, 2019
Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag).
Actelion's Opsumit fails in late-stage study of PAH due to Eisenmenger syndrome firstwordpharma
January 24, 2017
Actelion reported Monday that a late-stage study of Opsumit (macitentan) in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome failed to meet its primary objective.